Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine
pharmafile | February 11, 2026 | News story | Research and Development | Infinitopes, Oncology
Infinitopes, a clinical stage biotechnology company specialising in oncology, has announced the receipt of an additional $15.4m in seed funding, bringing its total raised funding amount to $35.1m.
The funding will assist Infinitopes in advancing its lead candidate ITOP1, a precision therapeutic vaccine designed to prevent the recurrence of oesophageal cancer. The company recently launched its first-in-human phase 1/2a VISTA trial of ITOP1, which will be conducted in NHS university cancer centres across the UK.
The trial can begin following Clinical Trial Application (CTA) approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Oesophageal cancer presents an area of high unmet medical need in the oncology sector. Risk factors for developing oesophageal cancer include age, alcohol use and tobacco use. It affects more men than women in the UK.
The latest round of funding for Infinitopes was co-led by Octopus Ventures and Amplify Bio. Other participants in the funding round included Macmillan Cancer Support, Cancer Research Horizons and Manta Ray Ventures.
Jonathan Kwok, CEO of Infinitopes, said: “This new funding unlocks our potentially groundbreaking phase 1/2a trial, enabling proof-of-concept evaluation of Infinitopes’ AI/machine learning-precision targeted, off-the-shelf vaccine platform to prevent recurrence after surgical resection. We aim to lead the development of innovative medicines that bring hope to patients suffering from cancers with unmet medical needs. We anticipate sharing our early findings at major conferences later this year.”
Elliot Hershberg, partner at Amplify Bio, added: “Recent clinical evidence has made it abundantly clear that the time for cancer vaccines is now. After years of searching, Infinitopes has clearly distinguished itself as the company positioned to drive this progress forward.”
Infinitopes is supported by Cancer Research UK and the University of Oxford. It combines work on the discovery of precision targets and on vector delivery systems to develop vaccines that tackle solid tumours.
Related Content
Infinitopes launches first-in-human trial of vaccine targeting oesophageal cancer
The cancer biotech company Infinitopes has gained approval by the UK Medicines and Healthcare products …
